Danish physicians' offices. We describe here a new design of external quality assessment wherein fresh, unstabilized whole-blood samples were analyzed by the physicians' office methods and by a hospital laboratory comparison method (glucose dehydrogenase assay, calibrated against NIST 909a). This approach was used in the offices of 171 general practitioners in our county during a 5-year period. The first survey, in 1992, revealed unsatisfactory performance in terms of our criterion that no difference between the physician's office and the hospital laboratory's single result should exceed ؎20% of the laboratory result. After initiation of a program of consultation and assistance, the proficiency testing rounds of 1994 and 1996 showed considerable improvement. Thus, whereas in 1992 12% of the values were outside the acceptance limits, in 1994 and 1996 the respective values were 4% and 3%. We believe the effect was mainly related to improvements in choice of technology, procedures, and handling of specimens. We conclude that the use of bedside instruments should be restricted to diagnosis of only severe hypo-or hyperglycemia and to monitoring glucose >5 mmol/L in already diagnosed diabetics. Our program differs from previous approaches to quality assessment and could also be useful for large hospitals' in-house proficiency testing.
Danish general practitioners (GPs) perform glucose measurements as a part of the traditional monitoring of glycemic control in patients with diabetes, and for diagnostic purposes. The number of glucose tests corresponds to 10% of all tests performed in GP offices, exceeded only by hemoglobin tests. On average, each GP office performs 350 blood glucose (B-glucose) measurements per year.
At present, there are no recommendations in Denmark concerning relevant use of B-glucose analysis and no quality demands, in contrast to US practice [1] . The introduction of a variety of different small instruments for performing near-patient testing in primary healthcare has revealed problems regarding quality assessment, quality assurance, and documentation.
Previous proficiency testing schemes for B-glucose have been hampered by the instability of glucose in whole blood. The stabilizers used interfere with some bedside test principles, according to instruction manuals for One Touch (LifeScan, Johnson & Johnson), Elite (Bayer Diagnostica), and Reflolux 2 (Boehringer Mannheim). Serum, which is more stable because of the absence of cells, is also unsuitable for some test methods (instruction manual for Companion Meter; MediSense). Therefore, in considering a new procedure for external glucose assessment, we formulated the following requirements and specifications for a control material and procedures:
1. Whole blood.
2. Anticoagulation without test interference. 3 . No addition of antiglucolytic agents. 4 . Three glucose concentrations in control material, from 2 to 20 mmol/L. 5 . No need for stable glucose or for knowing glucose value prior to analysis. 6 . Control material capable of yielding realistic and reliable estimates of performance with patients' samples, and reflecting the whole technical procedure as carried out in the office (including sampling of specimens, an important source of imprecision). 7 . Results expressed in relation to a comparison method by difference plot (there being no known "true" value determined).
From these specifications the materials and procedure were chosen and were tested for fulfillment of the criteria. Initial results with the system led to use of the method over a 5-year period-to assess both the quality of glucose measurements in general practice and the effect of the quality-assurance program so as to justify the expenses incurred.
Materials and Methods
The County of Vejle, Denmark, has 340 000 inhabitants and ϳ120 GP offices staffed with 211 doctors. In 1992, 98 of these practices with 171 doctors agreed to participate in a quality-assurance program involving visits by specially trained laboratory technologists, measurements of control materials, and support-on-demand for problems, all paid by the County health authorities.
control materials
Whole blood from a volunteer donor was anticoagulated with 12-30 IU/mL Li-Heparin (Monovette; Sarstedt) and was partially depleted of glucose, to ϳ2 mmol/L, by standing overnight at 22°C. The next morning we added glucose to 2 of the 3 aliquots of this sample to yield 3 different glucose concentrations (ϳ2, 7, and 15 mmol/L), and all 3 samples were taken to the GP offices by a technologist.
patients' samples
Capillary samples were taken from 2 to 4 visiting patients in each clinic, the same day, in the usual way, for the purpose of documenting the validity of this approach and also for determination of glucose content by both the method used in that clinic and the laboratory method. According to our procedure there was no need for the glucose concentration to be known in advance; we stabilized the concentration by adding hemolyzing agent at the same time that B-glucose concentration was being measured in the GP office.
gp office procedures
Control samples. The three aliquots prepared were carried by teaching laboratory technologists to the GPs and given to the GPs' staff, who determined B-glucose concentrations on these in duplicate, using their own instruments. At exactly the same time, the laboratory technologist mixed 20 L of each control blood in 1 mL of hemolyzing solution (cat. no.13888; Merck), also in duplicate. These test samples represented the "true" glucose concentration exactly at the time of analysis, because glycolysis was stopped and the hemolysates were stable for at least 24 h [2] . Moreover, the results obtained by the laboratory method were regarded as "true" values because results by this method in national and international external proficiency programs showed a bias range of only between Ϫ2% and ϩ2% (see Table 2 ).
Patients' samples. At exactly the same time, and from the same drop of blood from the patient, the laboratory technologist added 20 L of blood sample to 1 mL of hemolyzing solution, also in duplicate.
hospital laboratory glucose method
On the same day, the glucose concentration in hemolysates from the control samples and from the patients' samples from each GP was measured with a highly precise and highly accurate method in the Department of Clinical Chemistry by the glucose dehydrogenase method [3] . The reagent used was Unimate 7 Gluc GDH (Roche Diagnostica), analyzed with the Cobas Fara or Cobas Mira instruments (Roche). The method was calibrated against NIST 909a Standard Reference Material [4] .
definitions [5] and data analysis Imprecision (SD) was determined from duplicate determinations of the control samples and patients' samples by each GP office method. The percentage bias of a method was defined as the systematic deviation from the "true" value (hospital laboratory value), expressed as the difference between many measurements with the investigated GP office method and the "true" value.
The difference between the values obtained for a sample with the method under investigation and by the comparison method was calculated as the % difference between the first bedside test result and the mean of the duplicate determination in the laboratory. The first GP office determination was used because that is how results are produced in daily work there. The total error of a method, as a descriptive, statistical parameter, was expressed as bias Ϯ 1 SD, which includes the method's systematic deviation from the true value and the imprecision of the result obtained with that method.
Previously published criteria for evaluating tests [6] cannot be applied, because the control materials do not have assigned values but instead are measured with a comparison method/instrument. Hence % differences are calculated from the difference plot [7] , for the control materials as well as the patients' samples.
instruments
The bedside instruments used in 1992 were: Accutrend, Hypocount, and Reflolux (all from Boehringer Mannheim); Glucometer (Bayer Denmark A/S); HemoCue (HemoCue Denmark A/S); and MediSense. Since then, the technology has been extended with the Elite, One Touch, and Reflotron instruments. The measurement range of these is generally from 2 to ϳ25 mmol/L glucose. The HemoCue is mostly sold as a laboratory instrument; the other systems are primarily sold to patients and used for self-monitoring.
In all, during 1992, 338 single and 265 duplicate determinations were performed by the usual staff for 171 doctors in 98 offices, with use of 98 instruments of 6 different types. In 1994, 103 GP offices participated and in 1996, 120. The results of glucose measurements on control samples and capillary patients' samples by each instrument type were pooled and results by the different instruments were evaluated separately.
The validity of the control materials for use in this concept of performing external quality assurance was evaluated against actual patients' specimens by comparing bias and precision results for both types of blood for each of the different types of office instruments. In this part of the investigation we used the mean of duplicate determinations of both doctors' and laboratory results.
economy
Proficiency testing for B-glucose is a part of a general program for quality assurance of laboratory analysis in general practice in Vejle County. Four laboratory technologists and one chemist are involved in the project, an equivalent of one full-time employee being allocated to the program. The longest distance between a GP office and the nearest department of clinical chemistry is ϳ45 km. Again, all expenses are paid by our County's health authorities and no extra expenses are incurred by the GP offices.
ethics
The procedures followed in this study were in accordance with the Second Helsinki Declaration (amended in 1989), Danish law on biomedical research, and the Scientific Ethical Committee system of October 1, 1992. According to this, approval by a scientific ethical committee is not needed if only a part of the material is used for technical or quality-assurance purpose and no additional blood samples are taken. The local scientific ethical committee was informed about the study. All involved patients gave their informed consent before participation.
Results

validity of the control materials
For each instrument type, the average results of duplicate determinations for the same sample, both in doctor's offices and in the central laboratory, were recorded. The % difference was calculated for each sample, separately for capillary samples and for control materials.
The average % bias for both types of samples and for each instrument type is shown in Table 1 . Use of the control material was valid for proficiency testing for 4 instruments, giving differences that were not significant. For Accutrend and Exactech/MediSense, the possibility of systematic error caused by a matrix effect with the control material should be considered. (We observed that Exactech/MediSense is very sensitive for oxygen in the sample; this is not a problem when capillary samples are measured, but can be a source of error when venous blood is tested. An effective way to avoid this error would be to oxygenate samples just before measurement by extended mixing.) Nonetheless, the numerical differences were small (Table 1 ) and, though statistically significant, were considered to be of minor importance for the evaluation program. Consequently, the results from capillary blood and venous control samples were pooled.
Comparison of the results from the capillary and control material in 1994 and 1996, when new instruments types were tested, also showed no significant difference between these two types of control materials, and the results for both by each new instrument type were also pooled.
evaluation of instruments
To evaluate the instruments, we used the difference between the first result in the doctor's office and the mean of duplicate determinations with the laboratory method for both control materials and capillary samples for calculations of total error (which also includes imprecision of the method because the determinations reflect realistic circumstances of a single measurement in the doctor's office). The imprecision itself, however, was also evaluated on the basis of true duplicate determinations.
The imprecision of the different instruments is stated in Table 2 . In the reference interval for glucose, HemoCue gives results comparable with those by the laboratory method; i.e., 1 SD ϭ 0.11 mmol/L. The other instruments have imprecision between 0.26 and 0.48 mmol/L-values that are of course influenced by the limited number of determinations. Table 3 shows the total error results at all three control concentrations. Table 4 shows the frequency of results falling outside the acceptance range (i.e., Ϯ20% from the comparison method value; see Discussion). In 1992 there was no significant difference between the different instruments, but none could fulfill the goal of a maximum of Ϯ20% as acceptable error.
effect of the quality program on performance
In the second round, after presentation of results from the first round to the GPs, many offices replaced instruments and improved procedures, assisted by laboratory technologists. Results in the second and third rounds (1994 and 1996; Table 4 ) showed considerable improvement. 
Discussion
The optimal test material for quality assurance is, obviously, the actual blood from patients visiting doctors' offices. For practical reasons, however, additional control materials are needed to cover a larger range of glucose concentrations. Accordingly, we have introduced a new quality-assessment procedure for blood glucose determination in general practice. Because we deemed both the control material depleted in glucose and supplemented with glucose to suitable concentrations to be reasonably comparable with capil-lary blood taken from patients, the material could be used for quality evaluation of instruments of different types. The design of the control procedure involves the entire testing procedure in GP office; thus this quality assessment monitors not only instrument performance but also variations in practical handling, as the process was designed to closely resemble daily practice. (Only the blood simultaneously taken for determination by the comparison method was drawn by a professional laboratory technologist.)
An advantage of this procedure is that it can be performed over a span of time. The use of concentrationindependent materials makes timing flexible, and the process can be arranged at the convenience of the individual GP office and the laboratory. Furthermore, a GP showing unsatisfactory results can be assisted, corrected, and instructed, and the external quality assessment can easily be repeated just for that one.
The American Diabetes Association has recommended a maximum error of 10% (from a reference measurement value) for future instruments and 15% for existing instruments [8] . The NCCLS recommends that the discrepancy between the bedside result and a reference measurement should be Ͻ20% [9] . Recently, the Ϯ20% limit has also been used by the FDA in evaluation of over-the-counter B-glucose meters [10] . The general opinion among Danish medical professionals is that a Ϯ10% deviation from a reference value is good, between 10% and 20% is acceptable, and greater than this is unacceptable. In other words, it is an absolute demand that no single result is allowed to exceed the Ϯ20% limit.
For monitoring the treatment of diabetes, therefore, a CV Ͻ10%, corresponding to SD Ͻ0.7 mmol/L, seems reasonable [11] . All meters can comply with this (Table 2) . However, this only refers to the single instrument/practice, and as can be deduced from SD on total error, shown in Table 3 , the variation from practice to practice for use of the same instrument type far exceeds the single instrument's imprecision in reproducing its own results. This is important if a patient is monitored with different meters.
According to these criteria, the first proficiency testing round in 1992 showed unsatisfactory performance. Even though in our opinion the range of the area for acceptance (Ϯ20% as a total error) is extremely large, in 1992 no instrument type could comply (Table 4 ), and hence at that time we could not recommend diagnosis of diabetes in GP offices on the basis of results by such methods.
All results were anonymously reported back to the GPs, who evaluated their own results. Instrument vendors were also informed about results from the first round. They were very responsive, which in some cases resulted in changing calibrations, developing and standardizing the glucose test sticks, and improving manuals and instructions. We were very pleased to note this active interest and participation from commercial companies to improve the technical quality.
All doctors were visited by a laboratory technologist. 
Values shown are mean bias % Ϯ SD (and n).
As a consequence, many bought new instruments and asked for instruction from the central laboratory. After this, it was agreed to repeat proficiency testing. Results of the second proficiency testing round in 1994 showed considerable improvement (Table 4 ). We take this as an indication of the effect of a formalized quality-assurance program, which prompted doctors to improve procedures for handling patients, specimens, and testing. The improvement can be seen clearly in the low frequency of results exceeding Ϯ20% in the 1994 survey (Table 4 ). Several instrument types (Accutrend, HemoCue, One Touch) have no values outside this range, despite the greater number of determinations made. The quality level was maintained through the 1996 survey.
We attribute this considerable improvement for instrument-practice combinations to both better and morestandardized calibration of the machines, the mean total error being much reduced for Accutrend and HemoCue, and improved precision, probably induced by standardized sample handling after professional instruction. The fact that many GP offices switched to the HemoCue, which has better precision, also may account for part of the improvement. Table 4 shows a reduction in the SD of the mean for total error, both on the single machine and on mean bias %. Duplicate determinations confirm this: In 1996, the imprecision for Accutrend, Exactech/MediSense, and HemoCue was 0.25, 0.38, and 0.26 mmol/L, respectively ( Table 2) . One instrument, Hypocount, was no longer in use in 1996.
According to WHO [12] , the lower limit for fasting B-glucose in diabetes is 6.7 mmol/L. The broadly accepted upper reference limit for fasting B-glucose in nondiabetes is 6.0 mmol/L, a difference of 0.7 mmol/L. Thus, if a patient who has a true blood glucose value of 6 mmol/L should not falsely be classified as a diabetic, the glucose test should never yield a value Ͼ6.7 mmol/L for that patient's blood sample. From this and previous publications [8, 9, 11, 13] , and considering this difference to be clinical significant, we have formulated the following local performance goal for quality in glucose measurements to meet clinical needs: For diagnostic purposes, maximum allowable total error (e.g., numerical value of bias ϩ 2 SD) for the single instrument at 6 mmol/L should not exceed 0.7 mmol/L (12%). Generally, as it can be seen from Table 4 , bedside instruments cannot comply with this demand. Most will produce false-positive or falsenegative results, leading to incorrect diagnosis for the presence or absence of diabetes.
The problem of diagnosing hypoglycemia is outside the scope of this paper; but given that the lower acceptable glucose value for diabetics in treatment is 5 mmol/L and a further decrease to 4 mmol/L is expected to be important, an instrument or method should be capable of detecting this difference of 1.0 mmol/L [13, 14] . The critical difference between two consecutive results, i.e., the smallest change that makes them significantly differ- ent (P Ͻ0.05), has been defined as 2.77 ϫ CV [15] . For many GP office instruments, the CV at 4 -5 mmol/L is 10% (Table 2) . Hence, they can detect a change of 2.77 ϫ 10% ϭ 27.7%, corresponding to 1.4 mmol/L (from 5 to 3.6 mmol/L), but not a decrease from 5 to 4 mmol/L. In fact, glucose measurements on diabetes patients are used extensively, though not recommended by any Danish authority. Historically, GPs have handled diabetic patients for many years, and self-monitoring has been only slowly adopted by patients. We agree with American Diabetes Association [1] (and so do Danish diabetes specialists) that B-glucose should not be used by GPs to assess glycemic control in diabetes patients, but the tradition is difficult to change. Rather, the use of the described instruments should be restricted to screening for severe hypo-or hyperglycemia only and to monitoring glucose Ͼ5 mmol/L in already diagnosed diabetics.
Our experience with these small instruments is limited to GP offices only. Many diabetics use the same type of devices (except HemoCue, which is not handy enough and is too expensive for home use). Precision of all these instruments is satisfactory for self-monitoring. However, there is a big difference between use of an instrument by the same patient who uses it in the same (even if not quite correct) way every time, or by different staff at GP offices. And accuracy of home measurement is still a problem.
In GPs' offices, these instruments may be useful for educating diabetes patients in the understanding of their diseases, but their lack of accuracy and precision makes it impossible for the GP to check a patient's own reading on the patient's own instrument, and the combined error can produce severe differences in many instances.
With regard as to whether this type of proficiency testing program can be used generally, 98 GP offices (later 120, almost all) in Vejle County have participated voluntarily in a quality-assurance program involving visits by specially trained laboratory technologists. In connection with these annual visits, where we try to help the GPs' offices and solve their problems, we prepare the control samples and take them to the GPs' offices. Because this is also a part of our own quality-assessment program, it is difficult to calculate exact expenses concerning just this part of proficiency testing, but the cost could be prohibitive in sparsely populated areas because of the transportation expenses involved.
In conclusion, we have shown that this program for external quality assurance of GP office analyses is possible and also effective, in 5 years having contributed consid-erably to quality improvement in measurements of blood glucose in those offices. We propose that this system could be generally useful also in the hospital setting with decentralized satellite laboratories.
